neurocrin share year-to-d thought would time assess
potenti valu creation move though ramp orilissa
name royalti strong would hope
temper estim one gloss view ampl
runway continu aggress ingrezza growth tardiv dyskinesia td along
potenti addit contribut chorea associ huntington diseas
hd rel low-risk expans indic base dcf scenario contribut
td chorea combin peak sale exceedingli high gross
margin gm easili drive share north without contribut
pipelin asset beyond opicapon reiter overweight rate rais
pt see detail
plenti valu tabl per dcf scenario conserv scenario
reflect ingrezza contribut td near peak sale sale alreadi
annual near reflect pipelin contribut beyond
opicapon parkinson one could argu near fair valu
howev overli simplist way view share two main reason
ingrezza exceedingli high-gm product treatment set
character signific growth diagnosi rate along growth physician
recept inhibitor treatment refer physician survey
detail huntington chorea rel low-risk indic recal teva
inhibitor austedo approv ingrezza phase data expect
like td also rel low rate inhibitor treatment
note previous less treat patient inhibitor given
dynam combin contribut td chorea drive ingrezza sale
well north view upsid dcf scenario peak ingrezza sale
near translat valu per share north larger point
earn power ingrezza compel pipelin
congenit adren hyperplasia provid addit avenu valu creation
slower expect ramp orilissa endometriosi lost us
caveat tend take sanguin view opportun product
uterin fibroid uf partner raymond file nda august fda
action point envis greater leverag
payer uf set given rel pauciti treatment option realiti
surgic intervent uncommon real potenti favor
pharmaco-econom outcom orilissa uf howev lower orilissa
royalti estim mainli lower estim endometriosi dcf reflect
orilissa peak sale rang
clinic commerci setback relat ingrezza product
neurocrin focus therapi neurolog endocrin diseas
price close decemb
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
consensu
compani report factset pjc estim
new pt base price-to-earnings price-to-earnings ep
estim discount unchang two year
three year roll forward discount period use pt calcul revis
estim price-to-earnings better reflect aggress growth ingrezza due contribut
chorea associ huntington better reflect earn power associ
higher level ingrezza sale includ contribut expans indic
estim though temper estim orilissa royalti
reflect slower expect ramp lower estim overal endometriosi
particular believ ampl runway continu aggress ingrezza growth/adopt
point transform long-term earn growth potenti upsid extent
pipelin asset beyond opicapon bear fruit
page
million except per tardiv chorea licens fee incom expens tax incom outstand exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
includ cash cash equival short-term invest avail sale
compani report factset pjc estim
page
free chorea product licens fee good develop incom depreci oper provis incom oper depreci capit increas net work cash valu cash valu growth cash cash termin valu debt outstand valu per exhibit
ev equiti valu per share calcul use termin growth rate top wacc left assumpt
includ cash cash equival short-term invest avail sale
compani report factset pjc estim
page
free chorea product licens fee good develop incom depreci oper provis incom oper depreci capit increas net work cash valu cash valu growth cash cash termin valu debt outstand valu per quarterli annual incom statement
million except ep
ingrezza chorea huntington
mileston licens fee
sale
incom loss tax
expens total product sale
sale
gener administr
reflect mileston payment follow submiss snda file elagolix uterin fibroid
reflect in-process relat voyag collabor
proprietari piper jaffray decemb
current disclosur inform compani locat http //www piperjaffray com/researchdisclosur
